Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Lincoln Pharmaceuticals Ltd
Cash Equivalents
Lincoln Pharmaceuticals Ltd
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
|
Cash Equivalents
₹227.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash Equivalents
₹11.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash Equivalents
₹9.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
16%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash Equivalents
₹90.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash Equivalents
₹11.5B
|
CAGR 3-Years
49%
|
CAGR 5-Years
14%
|
CAGR 10-Years
7%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cash Equivalents
₹1.2B
|
CAGR 3-Years
-45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Lincoln Pharmaceuticals Ltd
Glance View
Lincoln Pharmaceuticals Ltd. is a holding company, which engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The firm offers products, such as tablets, capsules, liquid injection, cream in tubes, dry power injection, liquid in bott, liquid injection and pharma products. The company has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, vitamin-minerals and iron preparations, among others. The firm serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia and 26 States across India. The firm's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms) and Tinnex Capsule used to treat tinnitus.
See Also
What is Lincoln Pharmaceuticals Ltd's Cash Equivalents?
Cash Equivalents
227.8m
INR
Based on the financial report for Dec 31, 2024, Lincoln Pharmaceuticals Ltd's Cash Equivalents amounts to 227.8m INR.
What is Lincoln Pharmaceuticals Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
61%
Over the last year, the Cash Equivalents growth was -2%. The average annual Cash Equivalents growth rates for Lincoln Pharmaceuticals Ltd have been 20% over the past three years , 61% over the past five years .
You don't have any saved screeners yet